Germline intragenic mutations in the GNAS locus result in pseudohypoparathyroidism type 1a (PHP1a) and related conditions. Nearly half of the previously reported GNAS intragenic mutations were structural variants, including 3 tandem duplications of 12-25 bp. However, the precise mutation spectrum and the genomic basis of GNAS structural variants remain to be clarified. Here, we report a de novo 50-bp tandem duplication in GNAS (c.723_772dup50, p.Glu259Leufs*29) identified in a patient with typical clinical features of PHP1a. The mutant transcript was predicted to undergo mRNA decay or encode a nonfunctional protein. The 2 breakpoints of the duplication shared a 1-bp microhomology but were not associated with long homology or nucleotide stretches. We also examined the breakpoint structures of 3 previously reported GNAS duplications and found that 1 had a structure similar to that of our case, while the remaining 2 had blunt-ended breakpoints without microhomologies. In silico analyses revealed that the GNAS-flanking region was not enriched with repeats, palindromes, noncanonical DNA motifs, or GC content. This study expands the mutation spectrum of GNAS and provides the first indication that GNAS intragenic structural variants are induced by multiple processes, including nonhomologous end-joining and/or microhomology-mediated break-induced replication, independently of known rearrangement-inducing DNA features.

Keywords:
Chromosomal rearrangement, Duplication, Genome, indel, PHP
1.
Aldred MA, Trembath RC: Activating and inactivating mutations in the human GNAS1 gene. Hum Mutat 16:183-189 (2000).
2.
Conrad DF, Bird C, Blackburne B, Lindsay S, Mamanova L, et al: Mutation spectrum revealed by breakpoint sequencing of human germline CNVs. Nat Genet 42:385-391 (2010).
3.
Elli FM, de Sanctis L, Ceoloni B, Barbieri AM, Bordogna P, et al: Pseudohypoparathyroidism type Ia and pseudo-pseudohypoparathyroidism: the growing spectrum of GNAS inactivating mutations. Hum Mutat 34:411-416 (2013).
4.
Elli FM, Linglart A, Garin I, de Sanctis L, Bordogna P, et al: The prevalence of GNAS deficiency-related diseases in a large cohort of patients characterized by the EuroPHP Network. J Clin Endocrinol Metab 101:3657-3668 (2016).
5.
Froyen G, Belet S, Martinez F, Santos-Rebouças CB, Declercq M, et al: Copy-number gains of HUWE1 due to replication- and recombination-based rearrangements. Am J Hum Genet 91:252-264 (2012).
6.
Gu W, Zhang F, Lupski JR: Mechanisms for human genomic rearrangements. Pathogenetics 1:4 (2008).
7.
Kloosterman WP, Francioli LC, Hormozdiari F, Marschall T, Hehir-Kwa JY, et al: Characteristics of de novo structural changes in the human genome. Genome Res 25:792-801 (2015).
8.
Lemos MC, Thakker RV: GNAS mutations in pseudohypoparathyroidism type 1a and related disorders. Hum Mutat 36:11-19 (2015).
9.
Lykke-Andersen S, Jensen TH: Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes. Nat Rev Mol Cell Biol 16:665-677 (2015).
10.
Mantovani G, Spada A, Elli FM: Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues. Nat Rev Endocrinol 12:347-356 (2016).
11.
Ross MT, Grafham DV, Coffey AJ, Scherer S, McLay K, et al: The DNA sequence of the human X chromosome. Nature 434:325-337 (2005).
12.
Sano S, Iwata H, Matsubara K, Fukami M, Kagami M, et al: Growth hormone deficiency in monozygotic twins with autosomal dominant pseudohypoparathyroidism type Ib. Endocr J 62:523-529 (2015).
13.
Shaw CJ, Lupski JR: Implications of human genome architecture for rearrangement-based disorders: the genomic basis of disease. Hum Mol Genet 13:R57-R64 (2004).
14.
Shore EM, Ahn J, Jan de Beur S, Li M, Xu M, et al: Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 346:99-106 (2002).
15.
Thiele S, Mantovani G, Barlier A, Boldrin V, Bordogna P, et al: From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder (iPPSD), a novel classification proposed by the EuroPHP network. Eur J Endocrinol 175:1-17 (2016).
16.
Weinstein LS, Yu S, Warner DR, Liu J: Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev 22:675-705 (2001).
17.
Zhang F, Khajavi M, Connolly AM, Towne CF, Batish SD, Lupski JR: The DNA replication FoSTeS/MMBIR mechanism can generate genomic, genic and exonic complex rearrangements in humans. Nat Genet 41:849-853 (2009).
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.